Abstract 2095P
Background
Cancer-related fatigue (CRF) is a significant and frequent problem among cancer patients. There is no gold standard. However, ESMO CPGL 2020 recommended multimodal interventions, CRF is underdiagnosed, undertreated and underdocumented. In this study, we evaluated cancer rehabilitation program including education, physical activity and emotional support.
Methods
Cancer rehabilitation program includes: patients and family education, physical activity (aerobic exercise), water- therapy, yoga, behavioural therapy, relaxation, art, music-therapy, proteinrich nutrition, social support. The Five-time-sit-to-stand test, Hand-Grip-Strength, 6 min walking test, Brief fatigue inventory, Hospital anxiety and Depression scale were used. Descriptive statistics and t-tests.
Results
Participants were 112 patients (48y [29-75]), 60.7% women and 39.2% men. The primary cancer was 26.7 % breast, 16.9% gasrtoesophageal 33.6% colorectal, 16.8% lung, 5.96% pancreatobiliary. Before rehabilitation: the Five-time-sit-to-stand test 10.2 sec (4.5-28.1), Hand-Grip-Strength 28.4 kg, 6 min walking test 482 meters (49,631), Brief fatigue inventory 45 (0-75), Fatique 8/10 (0,10), Cognitive 6, Emotional 4, Physical 6, QoL 4 (0-10). HADS 8 (0, 18). After rehabilitation: the Five-time-sit-to-stand test 5.7 sec (-50%), Hand-Grip-Strength 39.2 kg, 6 min walking test 585 meters (62,822), Brief fatigue inventory 25 (0-58), Fatique 3/10 (0,10), Cognitive 3, Emotional 1, Physical 4, QoL 7 (0-10). HADS 4 (0, 18).
Conclusions
Cancer rehabilitation program including different types of interventions is effective in treating cancer related-fatigue.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06